Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
2FIRSTS | GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
2+ hour, 52+ min ago (900+ words) According to The Global State of Tobacco Harm Reduction 2026: A Situation Report, published by the Knowledge·Action·Change-operated Global State of Tobacco Harm Reduction project, about 200 million people worldwide now use non-combustible nicotine products including vapes, heated tobacco products, nicotine…...
FDA expands Bayer lung cancer drug approval
9+ min ago (183+ words) Today, we look at how regulators are trying to keep pace with agentic medical AI, see the FDA launch a project to examine why pregnancy registries struggle with enrollment, and more. Someone out there cure asthma, eh? It sucks. John…...
How SweTrial aims to bring more clinical trials to Sweden
42+ min ago (99+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. “We have no time to waste,” says Frida Lundmark, Head…...
AdventHealth Redmond Expands Lung Cancer Diagnostic Capabilities with Launch of Ion Robotic Bronchoscopy Platform
9+ min ago (200+ words) Posted by Staff Reports | Sep 10, 2026 | Floyd News, Top Local News | 0 | AdventHealth Redmond has launched the Ion robotic bronchoscopy platform, an advanced technology designed to enhance the evaluation and biopsy of pulmonary nodules and improve access to early lung cancer diagnosis…...
Cervical Cancer: Screening Rates Declining Among Women in Their 20s
8+ min ago (730+ words) Your hub for navigating cancer Tips and tools for managing your health and wellbeing during chemo Nearly 1 in 3 women ages 21 to 29 had never undergone cervical cancer screening as of 2023, according to new research published in JAMA Network OpenTrusted Source on…...
Elected leaders, candidates join in Voices for Cancer Care event
11+ min ago (231+ words) Cancer Support Community at Gilda’s Club will host an open house for elected officials and candidates from across Iowa and the club’s service area in Northwest Illinois to meet with those impacted by cancer. Voices for Cancer Care will be…...
Bayer receives FDA approval for first-line lung cancer therapy HYRNUO
20+ min ago (323+ words) Whippany-based Bayer said Sept. 9 that the U.S. Food and Drug Administration (FDA) granted accelerated approval to HYRNUO as a first-line treatment for certain adult patients with advanced non-small cell lung cancer. The approval covers adults with locally advanced or metastatic non-squamous…...
Loraine Fulton - Volunteer/Fundraiser of the Year
1+ hour, 2+ min ago (154+ words) Nominated by: Mike Brockbank THE Islander who helped turn the Hospice half-marathon into “one of the Island’s most successful and anticipated fundraising events” has been nominated for the Volunteer/Fundraiser of the Year award. Jersey Hospice Care volunteer manager Loraine…...
Rebecca Schnall Named Vice Dean for Research at Johns Hopkins School of Nursing
46+ min ago (412+ words) | Newswise Newswise Rebecca Schnall Named Vice Dean for Research at Johns Hopkins School of Nursing Newswise — Rebecca Schnall, PhD, MPH, RN-BC, FAAN, FACMI, will join the Johns Hopkins School of Nursing as faculty and Vice Dean for Research effective December…...
mRNA cancer vaccines’ biggest barriers to market
18+ min ago (672+ words) Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines. The personalized cancer vaccine field leaped forward last month when Merck and Moderna’s personalized melanoma vaccine scored big in a phase 3 clinical trial. Moderna’s…...